ArticleProtein & cell2015
To be EndMT or not to be, that is the question in pulmonary hypertension.
Article in Protein & cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Endothelial CPT2 loss impairs fatty acid oxidation and promotes renal fibrosis.Life metabolism · 2026Article
- Acetate Metabolism in Urological Health and Disease.Serican journal of medicine · 2024Article
- HOXB13-Mediated Lipid Metabolism Regulates Prostate Cancer Metastasis.Serican journal of medicine · 2024Article
- Endothelial deubiquinatase YOD1 mediates Ang II-induced vascular endothelial-mesenchymal transition and remodeling by regulating β-catenin.Acta pharmacologica Sinica · 2024Article
- Transcriptome analysis reveals molecular signature and cell-type difference of Homo sapiens endothelial-to-mesenchymal transition.G3 (Bethesda, Md.) · 2023Article
- Review
- Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways.International journal of medical sciences · 2022Article
- Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition.Frontiers in pharmacology · 2021Article
- Right atrial myxoma: a potential accelerator of pulmonary hypertension in the course of systemic sclerosis. The role of interleukin-6.Postepy dermatologii i alergologii · 2019Article
- Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases.Physiological reviews · 2019Review
- Reassessing endothelial-to-mesenchymal transition in cardiovascular diseases.Nature reviews. Cardiology · 2018Review
- Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?Matrix biology : journal of the International Society for Matrix Biology · 2016Review
- BMPR2 spruces up the endothelium in pulmonary hypertension.Protein & cell · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.